NeuroPace (NASDAQ:NPCE) Trading Down 4.1% – Should You Sell?

by · The Markets Daily

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report)’s stock price fell 4.1% during trading on Friday . The company traded as low as $16.13 and last traded at $15.8210. 129,261 shares changed hands during trading, a decline of 49% from the average session volume of 251,296 shares. The stock had previously closed at $16.50.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on NPCE shares. Zacks Research downgraded shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Leerink Partners restated an “outperform” rating and set a $19.00 price objective on shares of NeuroPace in a report on Wednesday, November 5th. Wells Fargo & Company lifted their target price on NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. increased their price target on NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, NeuroPace has a consensus rating of “Moderate Buy” and an average target price of $17.33.

Read Our Latest Stock Analysis on NeuroPace

NeuroPace Stock Performance

The company has a debt-to-equity ratio of 3.17, a current ratio of 4.86 and a quick ratio of 3.94. The company has a market cap of $547.28 million, a PE ratio of -21.62 and a beta of 1.90. The business has a fifty day simple moving average of $11.65 and a two-hundred day simple moving average of $11.12.

NeuroPace (NASDAQ:NPCE – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.09. The firm had revenue of $27.35 million during the quarter, compared to analyst estimates of $24.64 million. NeuroPace had a negative return on equity of 136.60% and a negative net margin of 25.28%. NeuroPace has set its FY 2025 guidance at EPS. Research analysts anticipate that NeuroPace, Inc. will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NPCE. First Light Asset Management LLC bought a new position in shares of NeuroPace during the 1st quarter worth approximately $19,468,000. Vanguard Group Inc. grew its holdings in NeuroPace by 4.9% in the third quarter. Vanguard Group Inc. now owns 1,435,850 shares of the company’s stock worth $14,804,000 after purchasing an additional 66,574 shares during the last quarter. Armistice Capital LLC increased its position in shares of NeuroPace by 12.6% during the third quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock worth $13,382,000 after purchasing an additional 145,665 shares in the last quarter. Deutsche Bank AG lifted its holdings in shares of NeuroPace by 124.0% during the 1st quarter. Deutsche Bank AG now owns 924,274 shares of the company’s stock valued at $11,359,000 after purchasing an additional 511,662 shares during the last quarter. Finally, Driehaus Capital Management LLC acquired a new stake in shares of NeuroPace in the 1st quarter worth $9,874,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

Read More